Researchers at Lund University are developing new methods for treating advanced prostate cancer by attacking stem cell-like cells that allow the disease to survive, spread and resist treatment.

Exploring the tumour biology of prostate cancer, the research group have now observed that the protein STAT3 is active in the stem cell-like cells. In their previous studies, they have proven that the natural compound galiellalactone affects STAT3 and has inhibitory effects on the growth of prostate cancer.
Through the development of new specific STAT3-inhibitors with galiellalactone as a model, the researchers hope to develop targeted therapies that attack the stem cell-like cancer cells in prostate cancer and prevent the tumour from growing and spreading.
The study was recently published in the online journal PLoS ONE.
Source-ANI
MEDINDIA



Email
![Prostate Specific Antigen [PSA] Prostate Specific Antigen [PSA]](https://www.medindia.net/images/common/patientinfo/120_100/prostate-specific-antigen.jpg)






